British Columbia Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

British Columbia Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12,349	Closed	-$920K	–	849
2021 Q1	$920K	Sell	12,349 -218	-2%	-$20.1K	0.01%	801
2020 Q4	$2.14M	Sell	12,567 -282	-2%	-$41.8K	0.02%	642
2020 Q3	$1.8M	Buy	12,849 +1,009	+9%	+$153K	0.01%	628
2020 Q2	$1.9M	Buy	11,840 +3,683	+45%	+$501K	0.02%	560
2020 Q1	$798K	Sell	8,157 -9,360	-53%	-$1.07M	0.01%	621
2019 Q4	$2.26M	Buy	17,517 +7,370	+73%	+$744K	0.02%	644
2019 Q3	$764K	Buy	+10,147	New	+$1.2M	0.01%	742

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

British Columbia Investment Management's SRPT Position: Q2 2021 in Review

British Columbia Investment Management sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 12,349 shares — an estimated $920K sold.

British Columbia Investment Management first reported a position in SRPT in Q3 2019 and held it in 7 quarters. The position peaked at $2.26M in Q4 2019. 331 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

British Columbia Investment Management reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
British Columbia Investment Management sold 12,349 Sarepta Therapeutics shares in Q2 2021, an estimated $920K.
British Columbia Investment Management first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 7 quarters.
British Columbia Investment Management's Sarepta Therapeutics position peaked at $2.26M in Q4 2019.
331 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on British Columbia Investment Management's 13F filing for Q2 2021, filed 9 Aug 2021.